John Birkmeyer named executive VP for enterprise support systems at Dartmouth-Hitchcock health system.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JOHN BIRKMEYER was named executive vice president for enterprise support services for the Dartmouth-Hitchcock health system.

Birkmeyer is the George D. Zuidema Professor of Surgery at the University of Michigan, and is head of the Center for Healthcare Outcomes and Policy. He also directs the Michigan Value Collaborative, a partnership between Blue Cross and Blue Shield of Michigan and leaders of 54 Michigan hospitals.

Between 1989, when he began his surgical residency, and 2004, when he was recruited to the University of Michigan, he served as chief of surgery at the White River Junction VA Medical Center, as chief of the section of general surgery at Dartmouth-Hitchcock, and as a core contributor to the Dartmouth Atlas of Healthcare. He was elected to the Institute of Medicine in 2006.

Birkmeyer’s research career has focused on understanding variation in surgical outcomes and cost-efficiency. He is also founder and chief scientific officer of ArborMetrix, a venture capital-funded analytics and services company.

YOU MAY BE INTERESTED IN

New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month.

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login